The assay reproduced MG disease biology in vitro and showed that 12 out of 19 patients (patient categories 1 + 2) had clear C7-dependent loss of AChRs (Table 1), identifying a subset of patients with pronounced complement involvement and therefore likely to benefit from terminal pathway complement therapy. Here, C7 is linked to myasthenia gravis.